Company intelligence / Profile preview

Blue Cell Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

A phase I clinical trial using autologous adipose-derived stem cells showed promising results—8 out of 11 urine-continent men regained erectile function after treatment. The company has since shifted focus to developing a standardized allogeneic ("off-the-shelf") version with enhanced scalability and efficacy. Preclinical data suggest superior outcomes compared to autologous approaches. No large-scale or late-stage clinical results have been published yet

Therapeutic areas: Men's Health
Modalities: Allogeneic stem cell therapy (specifically "Blue Cells," a proprietary population of stem cells derived from adipose tissue)
Industry: Biotech

Drug pipeline

1 asset

BlueC-231

Preclinical

Partnerships

University of Southern Denmark (licensing partner)Odense University HospitalNovozymessupported by Eurostars grant funding

Beyond the preview

Go deeper on Blue Cell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Cell Therapeutics.

Explore the full profile